Return on Equity (ROE)
Updated 536h ago
Sector Performance
85th percentileDLTR
34.0%
Sector Median
13.8%
Sector Avg
31.4%
Deep Analysis
Return on Equity (ROE) measures how much profit a company generates for each dollar of shareholders' equity.
DLTR’s current ROE of 34.0% means it earns $0.34 for every dollar of equity, well above the sector median of 13.8%, placing it in the 84th percentile among peers. However, no year-over-year or quarter-over-quarter changes are available (N/A), and the trend over the last eight quarters is also N/A, so there is no data to assess whether this high ROE is improving or weakening. The combination of a very high ROE level with no trend information suggests a potential opportunity from strong current profitability, but also adds risk because you cannot gauge its consistency. This metric supports the overall NEUTRAL verdict: the ROE is excellent for a single snapshot, but without trend data, the assessment cannot be upgraded to bullish or downgraded to bearish.
Frequently Asked Questions
What does the Return on Equity (ROE) tell investors about DLTR?
ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.
How is the Return on Equity (ROE) calculated?
Return on Equity (ROE) is calculated as: Net Income / Shareholders' Equity.
Who are DLTR's closest peers by Return on Equity (ROE)?
The closest peers by Return on Equity (ROE) include: MRNA (-36.6%), FICO (-37.3%), XRAY (-37.7%), VRSN (-38.3%), MSCI (-45.3%).
The Formula
Net Income / Shareholders' Equity
Why It Matters
ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.
Master DLTR's Valuation
Get the complete institutional research report covering all fundamental and technical metrics.
View full DLTR research report →DLTR
34.0%
Sector Median
13.8%
Sector Avg
31.4%
How DLTR's Return on Equity (ROE) compares to sector peers.
Also Analyze
Not financial advice. Research tool only. Data may be delayed.